Comparative clinical study with iotrolan versus metrizamide in lumbar myelography
Inoue, S.; Watanabe, T.; Yamamura, H.
Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband 128: 161-166
1989
ISSN/ISBN: 0178-4609 PMID: 2568787 Document Number: 340314
In order to examine the radiopacity, safety, and usefulness of iotrolan, a new dimeric, nonionic, water-soluble contrast medium for myelography, a multicenter clinical study was performed in lumbar myelography using metrizamide as the reference drug. Both media were injected at a strength of 190 mg I/ml in 90 patients each. Both contrast media showed good opacification; there was no significant difference between the two media. The incidence and severity of side effects were significantly lower with iotrolan than those with metrizamide. No severe side effects, such as convulsion and shock, were observed with either medium.